THER-09. ONCOLYTIC ADENOVIRUS, DNX-2401, FOR NAIVE DIFFUSE INTRINSIC PONTINE GLIOMAS: A PHASE I CLINICAL TRIAL

The objective of this trial is to determine the safety, tolerability, and toxicity of DNX-2401 in newly diagnosed DIPG patients (NCT03178032) followed by radiotherapy. Secondary endpoints are overall survival at 12 months, percentage of responses and induced immune response against tumor. Tumor biop...

Descripción completa

Detalles Bibliográficos
Autores principales: Iñigo-Marco, Ignacio, Gonzalez-Huarriz, Marisol, García-Moure, Marc, Tamayo, Ibon, Hervas, Sandra, Hernandez, Ruben, Buñales, Maria, DeAndrea, Carlos, Villalba, Maria, Jones, Chris, MacKay, Alan, Hulleman, Esther, Van der Lugt, Jasper, Aldave, Guillermo, Lopez-Ibor, Blanca, Patiño-Garcia, Ana, Diez-Valle, Ricardo, Fueyo, Juan, Gomez-Manzano, Candelaria, de Larraya, Jaime Gallego Perez, Tejada, Sonia, Alonso, Marta M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Viral/Gene Therapy and other Novel Therapies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715674/
http://dx.doi.org/10.1093/neuonc/noaa222.859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715674/
http://dx.doi.org/10.1093/neuonc/noaa222.859

Ejemplares similares